Literature DB >> 23080290

Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.

Dolly Sharma1, Wendy Baughman, Amy Holst, Stephanie Thomas, Delois Jackson, Maria da Gloria Carvalho, Bernard Beall, Sarah Satola, Robert Jerris, Shabnam Jain, Monica M Farley, J Pekka Nuorti.   

Abstract

BACKGROUND: Nasopharyngeal (NP) carriage and invasive pneumococcal disease (IPD) attributable to serotypes in the 7-valent pneumococcal conjugate vaccine (PCV7) declined dramatically after vaccine introduction, whereas non-PCV7 serotypes increased modestly. Characteristics of pneumococcal carriage and IPD among children in Atlanta, GA, were compared during 2 time periods: before PCV7 introduction and before 13-valent PCV (PCV13) introduction.
METHODS: NP swabs from 231 and 451 children 6-59 months old receiving outpatient medical care were obtained in 1995 and 2009, respectively. A total of 202 and 47 IPD cases were identified in children younger than 5 years of age in 1995 and in 2008 to 2009, respectively, through active, population-based surveillance in Atlanta. Isolates were serotyped, sequence-typed (ST) and tested for antimicrobial susceptibility.
RESULTS: Forty percent (93/231) of children in 1995 and 31% (139/451) in 2009 were colonized with Streptococcus pneumoniae; 60% and 0.7% were PCV7 serotypes, respectively. In 1995, PCV7 serotypes accounted for 83% and 19A accounted for 5% of IPD compared with no PCV7 serotypes and 19A accounting for 49% of IPD in 2009 (P < 0.001). In 2009, PCV13 serotypes accounted for 22% of carriage (mostly 19A) and 60% of invasive isolates (P < 0.001). ST320 accounted for 66% and 52% of 19A carriage and IPD isolates in 2009, respectively; all ST320 isolates were multidrug-resistant. No ST320 NP or IPD isolates were identified before PCV7.
CONCLUSIONS: Serotype distribution among NP and IPD isolates in Atlanta has shifted to non-PCV7 serotypes; 19A was the leading serotype for both. The multidrug-resistant ST320 strain was responsible for two-thirds of 19A carriage isolates and half of IPD isolates. The predominance of serotype 19A in carriage and IPD among children in Atlanta highlights the potential direct and indirect benefits anticipated by implementation of PCV13 in the community.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23080290     DOI: 10.1097/INF.0b013e3182788fdd

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  37 in total

1.  Occult bacteremia etiology following the introduction of 13-valent pneumococcal conjugate vaccine: a multicenter study in Spain.

Authors:  Susanna Hernández-Bou; Borja Gómez; Santiago Mintegi; Juan J García-García
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-07       Impact factor: 3.267

2.  Invasive pneumococcal disease in children can reveal a primary immunodeficiency.

Authors:  Jean Gaschignard; Corinne Levy; Maya Chrabieh; Bertrand Boisson; Cécile Bost-Bru; Stéphane Dauger; François Dubos; Philippe Durand; Joël Gaudelus; Dominique Gendrel; Christèle Gras Le Guen; Emmanuel Grimprel; Gaël Guyon; Catherine Jeudy; Eric Jeziorski; Francis Leclerc; Pierre-Louis Léger; Fabrice Lesage; Mathie Lorrot; Isabelle Pellier; Didier Pinquier; Loïc de Pontual; Philippe Sachs; Caroline Thomas; Pierre Tissières; Frédéric V Valla; Philippe Desprez; Véronique Frémeaux-Bacchi; Emmanuelle Varon; Xavier Bossuyt; Robert Cohen; Laurent Abel; Jean-Laurent Casanova; Anne Puel; Capucine Picard
Journal:  Clin Infect Dis       Date:  2014-04-23       Impact factor: 9.079

3.  Impact of 13-Valent Pneumococcal Conjugate Vaccination on Streptococcus pneumoniae Carriage in Young Children in Massachusetts.

Authors:  Grace M Lee; Ken Kleinman; Stephen I Pelton; William Hanage; Susan S Huang; Matthew Lakoma; Maya Dutta-Linn; Nicholas J Croucher; Abbie Stevenson; Jonathan A Finkelstein
Journal:  J Pediatric Infect Dis Soc       Date:  2013-10-03       Impact factor: 3.164

4.  Preventing non bacteremic pneumococcal pneumonia in older adults: historical background and considerations for choosing between PCV13 and PPV23.

Authors:  David S Fedson
Journal:  Hum Vaccin Immunother       Date:  2014-04-14       Impact factor: 3.452

5.  Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agents.

Authors:  Rodrigo E Mendes; Donald Biek; Ian A Critchley; David J Farrell; Helio S Sader; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

Review 6.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

7.  Noninvasive Streptococcus pneumoniae serotypes recovered from hospitalized adult patients in the United States in 2009 to 2012.

Authors:  Rodrigo E Mendes; Rosalind C Hollingsworth; Andrew Costello; Ronald N Jones; Raul E Isturiz; Dial Hewlett; David J Farrell
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

8.  Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage Among American Indians.

Authors:  Lindsay R Grant; Laura L Hammitt; Sarah E O'Brien; Michael R Jacobs; Connie Donaldson; Robert C Weatherholtz; Raymond Reid; Mathuram Santosham; Katherine L O'Brien
Journal:  Pediatr Infect Dis J       Date:  2016-08       Impact factor: 2.129

9.  Radical serotype rearrangement of carried pneumococci in the first 3 years after intensive vaccination started in Hungary.

Authors:  Adrienn Tóthpál; Szilvia Kardos; Krisztina Laub; Károly Nagy; Tamás Tirczka; Mark van der Linden; Orsolya Dobay
Journal:  Eur J Pediatr       Date:  2014-09-02       Impact factor: 3.183

Review 10.  13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents.

Authors:  Greg L Plosker
Journal:  Paediatr Drugs       Date:  2013-10       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.